Aktiesnakken — Juni 2010
-
hvad er grunden til deres nye target, solsen?
-
det er helt skævt
-
i det nuværende kursleje er det vel egentlig ligegyldigt om de siger 25% eller 50%
-
det giver jo stort set samme resultat
-
Super solsen. Det er prof arbejde i gen
-
We value Genmab using a probability weighted DCF based model that yields a
reduced fair value of DKK63, adjusting for currency (down from DKK72).
However, we introduce a 25% refinancing discount that yields our reduced DKK44
price target that makes us dow -
ok - hvis de mener det, så er der jo ikke meget værdi i casen
-
men med dagens udvikling - så skal de jo opgradere igen i aften...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind